V Usonis1, V Bakasenas, M Denis. 1. Centre of Pediatrics, Vilnius University, Lithuania. usonis@ktl.mii.lt
Abstract
BACKGROUND: We have previously shown that a new measles, mumps, rubella (MMR) vaccine, Priorix, with a novel mumps component elicits anti-mumps antibody titers comparable to the licensed M-M-R II vaccine. MATERIALS AND METHODS: To ensure that these antibodies had neutralizing activity against wild-type mumps virus, sera were prepared 2 and 18 months after vaccination of 12-24-month-old infants with either Priorix or M-M-R II and ELISA antibody titers and neutralizing activity were determined. RESULTS: After 2 months, Priorix and M-M-R II vaccines elicited comparable ELISA antibody titers and neutralizing activity. At 18 months ELISA seropositivity rates were 80-81% and 94-96% of vaccinees had neutralizing activity. All ELISA seropositives had neutralizing activity. CONCLUSION: These data suggest that both vaccines provided equivalent protection against mumps over this 18-month period.
BACKGROUND: We have previously shown that a new measles, mumps, rubella (MMR) vaccine, Priorix, with a novel mumps component elicits anti-mumps antibody titers comparable to the licensed M-M-R II vaccine. MATERIALS AND METHODS: To ensure that these antibodies had neutralizing activity against wild-type mumps virus, sera were prepared 2 and 18 months after vaccination of 12-24-month-old infants with either Priorix or M-M-R II and ELISA antibody titers and neutralizing activity were determined. RESULTS: After 2 months, Priorix and M-M-R II vaccines elicited comparable ELISA antibody titers and neutralizing activity. At 18 months ELISA seropositivity rates were 80-81% and 94-96% of vaccinees had neutralizing activity. All ELISA seropositives had neutralizing activity. CONCLUSION: These data suggest that both vaccines provided equivalent protection against mumps over this 18-month period.
Authors: Andrea A Berry; Remon Abu-Elyazeed; Clemente Diaz-Perez; Maurice A Mufson; Christopher J Harrison; Michael Leonardi; Jerry D Twiggs; Christopher Peltier; Stanley Grogg; Antonio Carbayo; Steven Shapiro; Michael Povey; Carmen Baccarini; Bruce L Innis; Ouzama Henry Journal: Hum Vaccin Immunother Date: 2017-05-08 Impact factor: 3.452